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Abstract
This paper reviews milestones in antidotal therapies 
for cyanide (CN) spanning early remedies, current 
antidotal systems and research towards next genera-
tion therapies. CN has been a part of plant defense 
mechanisms for millions of years. It became industrially 
important in the nineteenth century with the advent 
of CN assisted gold mining and the use of CN as 
a pest control agent. The biochemical basis of CN 
poisoning was actively studied and key mechanisms 
were understood as early as 1929. These fundamental 
studies led to a variety of antidotes, including indirect 
CN binders that generate methemoglobin, direct CN 
binders such as hydroxocobalamin, and sulfur donors 
that convert CN to the less toxic thiocyanate. Research 
on blood gases at the end of the twentieth century shed 
new light on the role of nitric oxide (NO) in the body. 
The discovery of NO’s ability to compete with CN for 
enzymatic binding sites provided a previously missed 
explanation for the rapid efficacy of NO generating 
antidotes such as the nitrites. Presently used CN thera-
pies include: methemoglobin/NO generators (e.g. , 
sodium nitrite, amyl nitrite, and dimethyl aminophenol), 
sulfur donors (e.g. , sodium thiosulfate and glutathione), 
and direct binding agents [(e.g. , hydroxocobalamin 
and dicobalt salt of ethylenediaminetetraacetic acid 
(dicobalt edetate)]. A strong effort is being made to 
explore novel antidotal systems and to formulate them 
for rapid administration at the point of intoxication in 
mass casualty scenarios. New antidotes, formulations, 
and delivery systems are enhancing bioavailability 
and efficacy and hold promise for a new generation of 
improved CN countermeasures.
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therapies for cyanide (CN) spanning early history, 
current antidotal systems, and research towards next 
generation therapies. Presently used CN therapies 
include: methemoglobin/nitric oxide generators (e.g. , 
sodium nitrite, amyl nitrite, and dimethyl aminophenol), 
sulfur donors (e.g. , sodium thiosulfate and glutathione), 
and direct binding agents (e.g. , hydroxocobalamin 
and dicobalt edetate). New antidotes, formulations, 
and delivery systems are presently being developed 
for rapid administration at the point of intoxication in 
mass casualty scenarios. These hold promise for a new 
generation of improved CN countermeasures.
Petrikovics I, Budai M, Kovacs K, Thompson DE. Past, present 
and future of cyanide antagonism research: From the early 
remedies to the current therapies. World J Methodol 2015; 5(2): 
88-100  Available from: URL: http://www.wjgnet.com/2222-0682/
full/v5/i2/88.htm  DOI: http://dx.doi.org/10.5662/wjm.v5.i2.88
INTRODUCTION
Cyanide (CN) refers to both the anion CN- and the 
undissociated form of hydrogen cyanide (HCN). It is a 
weak acid with a pKa of 9.2, therefore at the body’s pH 
it exists mainly in the HCN form. HCN can easily cross 
cellular, and subcellular membranes such as the blood 
brain barrier, and mitochondrial membranes.
CN is formed and is present in various spheres of 
Nature, such as the cosmos, volcanic eruptions, and 
lightning[1]. Certain plants, fungi, bacteria, and animals 
synthesize CN as a component of cyanogenic glycosides 
to provide a source of nitrogen and for self-defense[2,3]. 
Consuming cyanogenic plants (e.g., cassava roots, 
yams, sorghum, maize) without proper preparation 
can lead to CN intoxication. The cyanogenic glycoside 
amygdalin is present in some pitted fruits like bitter 
almond, and apricot cherries[4]. Cyanogenic glycosides 
can eliminate HCN through a hydrolytic reaction[5]. 
Metabolism of other cyanogenic chemicals such as 
the cyanogen halides, and nitriles also leads to CN 
intoxication[6]. 
CN is present in smoke from fires (especially bur-
ning acrylonitrile, polyurethane, polyamide, wool, silk, 
rubber) and cigarettes[7-9]; in the vasodilating agent 
Nitroprusside (formulated as a CN complex)[10,11]; and in 
industrial settings where CN is widely used to complex 
metals - for example, CN is widely used in industry for 
gold extraction from ores[12].
CN has been used as a poison from antiquity. It was 
first isolated from cherry laurel[13]. Early CN poisonings 
were reported more than 200 years ago by Wepfer in 
1679, and by Fontana in 1795[13], however, the first 
attempt to antagonize CN was reported later, in the 19th 
century[14]. Theories, based on biochemical mechanisms 
of CN antagonism were reported in the mid-20th 
century[15-20] and therapeutic agents became available 
for clinical application. After the recent recognition of CN 
as a military weapon and terror agent, intense research 
has led to a deeper understanding of CN biochemistry, 
and has fostered the development of novel CN 
countermeasures.
CN was used as a chemical weapon for the first time 
in World War I. In World War II the Nazi’s used CN in 
gas chambers[21]. In the 1980’s Iraq used CN against 
the Kurds[22]. CN was also involved in the Tokyo subway 
attack in 1995[23], in the first World Trade Center attack in 
1993[24], and in the Chicago Tylenol disaster in 1982[25]. 
FROM RESEARCH TO THERAPY
Mechanism of cyanide toxicity/search for diagnostics 
The primary biochemical basis of CN poisoning was 
known and published as early as 1929[26]. CN binds 
and inactivates several metal-containing enzymes, but 
the most important effect is attributed to the binding 
of Cyt c Oxidase, which is the terminal oxidase of the 
mitochondrial electron transport chain. This results in 
histotoxic hypoxia, due to the inhibition of cell oxygen 
utilization. As the result of suppressing the aerobic 
metabolic pathway, the less efficient anaerobic pathway 
becomes dominant, and pyruvate is reduced to lactic 
acid. The resultant acidosis leads to central nervous 
system (CNS) and myocardial depressions.  
Higher CN doses (higher than 5XLD50) generate 
more complex responses[27]. For example, at higher 
doses, CN induces pulmonary arteriolar and coronary 
vasoconstriction that can result in cardiogenic shock/
pulmonary edema[28], and stimulates chemoreceptors 
in the carotid artery and aorta resulting in hyper apnea. 
The antidotal effects of the vasodilators (e.g., nitrites) 
and alpha-adrenergic blockers (e.g., phenoxybenzamine) 
confirmed the vascular effects of CN, that are present 
along with the earlier discovered biochemical enzyme 
binding effects[29].
Lower doses of CN cause responses such as dizziness, 
headache, nausea, and vomiting as a result of inhibiting 
and interfering with the cellular enzymes. Chronic 
low dose CN exposure can result in Parkinson-like 
syndromes, confusion, and intellectual deterioration[30]. 
It is suggested that the wide-spread pathologic condition 
of tropic ataxic neuropathy is associated with the 
intense consumption of cassava with high CN-Glycoside 
content[31].
HCN absorbs rapidly through the mucus membranes 
and the skin. Inhaling HCN results in rapid intoxication, 
and if concentrations are high enough, death. When 
salts are ingested, the absorption from the GI tract is 
slower.  About 60% of the absorbed CN binds to protein. 
It has high affinity to Cobalt and Fe3+, but it also reacts 
with sulfur containing molecules in the body (see next 
paragraphs). 
The diagnosis of CN intoxication is difficult in the 
absence of a direct assay for CN; however, cardiova-
scular and CNS depressions in smoke inhalation 
victims always suggest CN involvement. Generally, 
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symptoms, such as metabolic acidosis, coma, shock, 
seizures, bradycardia, are not specific, but if the 
patient is randomly collapsed, and not responding to 
oxygen treatment, CN exposure should be suspected. 
Laboratory tests can show saturated hemoglobin 
(Hgb) (oxygen is not utilized), lactic acidosis (blocked 
oxidative phosphorylation), and hyperglycemia (toxic 
effects on pancreatic beta-cells)[32]. CN caused death 
is confirmed chemically using a colorimetric test at the 
scene of the crime[33], followed by analysis by GC-MS[34]. 
Due to the relatively short half-life of CN in the blood[35], 
detecting major metabolites such as thiocyanate (SCN) 
and 2-aminothiazoline-4-carboxylic acid (ATCA) are 
recommended[36,37]. ATCA, as a stable CN metabolite 
has been established as an important forensic CN 
biomarker[38]. A recent review of the analysis of CN and 
its metabolites was published by Logue et al[39] in 2010. 
Cyanide metabolism 
Small amounts of CN can be metabolized in the body 
by various endogenous metabolic pathways, however, 
the rate of detoxification is slow (about 0.017 mg 
CN/body weight/min). The body can metabolize CN 
at even the lethal dose, if that is given slowly over 
the course of several hours[40]. In the most important 
endogenous detoxification reaction CN is converted 
to the less toxic SCN by reaction with thiosulfate and 
other endogenous sulfur donors in the presence of a 
sulfurtransferase enzyme, Rhodanese (Rh). Since Rh is 
a mitochondrial enzyme, and the inorganic thiosulfate 
has limited cell penetration capability, the serum 
albumin-sulfane complex plays a major role in ferrying 
sulfur donors to Rh[41]. Endogenous sulfur donors are 
formed from cysteine and methionine in the presence 
of sulfurtransferases such as Rh, Mercaptopyruvate 
Sulfur Transferase and Cystathionase. The second 
most important metabolic pathway is the formation of 
the chemically stable CN metabolite, ATCA, when CN 
reacts with endogenous cysteine[37]. Another important 
metabolic pathway is the formation of cyanocobalamin 
from hydroxocobalamin. These metabolic end-products 
are excreted by the urine, while unreacted CN is 
excreted in breath, urine and sweat. The most recent 
understanding of CN metabolism, the role of nitric oxide 
(NO) will be discussed in the next section.
Milestones in CN antagonism
At the end of the 19th and beginning of the 20th century 
scientists began a systematic search for ways of 
neutralizing the toxic effects of the deadly chemical. 
These investigations of CN antagonism prior to the 
1930s resulted in the development of the classic CN 
therapies such as of sodium thiosulfate and sodium 
nitrite that are still in use worldwide. Table 1 lists some 
important therapies and the countries where they are 
presently employed in treating CN intoxication.
Methemoglobin formers: Historically the first CN 
poisoning remedy was the methemoglobin former amyl 
nitrite[42]. In studies on the biochemical mechanism 
of CN antagonism, it was found that while CN has 
low affinity to Hgb, it has high affinity to the oxidized 
form of Hgb, methemoglobin (MetHgb), resulting in 
the formation of the relatively stable cyano-MetHgb 
complex[15,16]. Amyl nitrite, the first MetHgb former 
used for CN antagonism, was followed subsequently 
by sodium nitrite. As early as 1933, the combination 
of the MetHgb formers amyl nitrite, sodium nitrite and 
sodium thiosulfate was reported to show significant 
enhancement in antidotal protection[15,16]. To overcome 
the disadvantage of the slow MetHgb formation by 
nitrites, a fast MetHgb former, 4-dimethylaminophenol 
(DMAP), was developed and investigated[43-45]. When 
DMAP was administered intravenously, CN was entrap-
ped within the red blood cells with relatively high 
efficiency[46]. This fast acting MetHgb former was deve-
loped and used in Germany in the military and civilian 
population. It produced 2-3 x LD50 protection in a dog 
model when the MetHgb level was kept around 30%[47]. 
Similar CN antidotal protections were found with other 
MetHgb formers such as p-aminopropiophenone (PAPP), 
p-aminoheptanoylphenone, and hydroxylamine[48]. 
Sulfane sulfurs and sulfur donors as CN antidotes: 
As early as 1894 Lang[49] reported that sodium thio-
sulfate antagonizes CN intoxication by converting it to a 
biologically less active metabolite in rabbits. Pascheles[50] 
and Kahn[51] pointed out that in the liver enzymes 
enhanced the transformation of CN to SCN. During 
that time other endogenous organo sulfur molecules, 
such as cysteine, cystine and glutathione were also 
investigated as CN antidotes[52-54]. 
In parallel with the MetHgb binding theory reported 
by Chen et al[15] in 1933, Lang[55] reported the biotrans-
formation reaction between CN and thiosulfate, in which 
thiosulfate served as a sulfur donor substrate for the 
mitochondrial sulfurtransferase, Rh. Investigating the 
substrate specificity of Rh, Sorbo reported that sulfur 
donors, such as aliphatic and aromatic thiosulfonates 
are superior sulfur donors than thiosulfate[56]. Rh (E.C. 
2.8.1.1; thiosulfate:cyanide sulfurtransferase) was the 
first sulfurtransferase that was studied in detail[57,58]. The 
utilization of thiosulfate as CN antidote was reported to 
be limited by its short biological half-life, small volume 
of distribution, and limited ability to penetrate the 
mitochondrial membranes to reach the Rh enzyme[41]. 
Frankenberg et al[59] reported in 1975 that the presence 
of CN enhanced the cell penetration capability of 
thiosulfate, making thiosulfate more efficient as a 
therapeutic agent, rather than as a prophylactic agent. 
Sulfane sulfur molecules (containing multiple divalent 
sulfur atoms bound to each other) can serve as a sulfur 
donor to the Rh reaction. In 1981, Westley[60] reported 
that a series of sulfane sulfur compounds, such as 
thiosulfonates, polythionates persulfides, polysulfides, 
and elementary sulfur serve as substrates for the Rh 
reaction, however, the pharmacokinetic parameters and 
toxicity of some of these compounds limited their usage 
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antidotal effects of thiosulfate, and the thiosulfate + 
nitrite combination[70]. 
Oxygen/hyperbaric oxygen: The Way lab reported 
first the CN antidotal effect of Oxygen/Hyperbaric 
oxygen[71-73]. Oxygen alone does not protect against CN, 
but it does enhance the effects of thiosulfate and the 
thiosulfate + nitrite combination[74]. 
Way - classification of CN antidotes: Way[19] sum-
marized the mechanisms of CN antagonism and 
classified the CN antagonists known at that time. For 
example, he described the four major steps involved 
in the antagonism of CN by nitrites and thiosulfate: 
(1) CN binds to Cytochrome C Oxidase to form CN- 
Cytochrome C Oxidase; (2) nitrite reacts with Hgb to 
form MetHgb; (3) CN binds to MetHgb to form Cyano-
MetHgb; and (4) thiosulfate reacts with CN to form 
SCN. This mechanism explained how the classic CN 
therapy (thiosulfate + nitrite) works, how CN partitions 
between Cytochrome c Oxidase and MetHgb until it is 
eventually converted to SCN and eliminated from the 
body by the urine. 
Way described four basic classes of CN antagonists: 
(1) class I: Cyanide Binders: Class IA: MetHgb 
formers (such as nitrites and DMAP); Class IB: Cobalt 
compounds (such as dicobalt edetate and Hydroxo-
cobalamin); Class IC: Carbonyl compounds (such 
as pyruvate); (2) class II: Sulfur Donors:  Class IIA: 
Thiosulfate; Class IIB: Thiosulfonates; Class IIC: Other 
Sulfur sulfanes; (3) class III: Cyanide Binders and Sulfur 
Donors: such as mercaptopyruvate; and (4) class IV: 
Unknown Mechanism: Class IVA: Oxygen; Class IVB: 
Chlorpromazine. 
New antidotal approach and new sulfur donor 
combination studies in the 20th century: The 
lower in vivo antidotal efficacy of thiosulfate relative 
to its in vitro efficacy highlighted how the limited cell 
penetration capability of thiosulfate adversely impacted 
its ability to reach the mitochondrial Rh[75]. Early 
investigations indicated the importance of externally 
administered Rh directly to the circulation to enhance 
the CN antidotal effect of thiosulfate[43,76-78]. However, 
when proteins (enzymes) are injected directly to the 
bloodstream, they are rapidly destroyed by proteolytic 
enzymes and the body’s immune system. Therefore, 
the efficiency of this approach is limited[79]. To minimize 
the adverse immunologic reactions, a protective 
as CN antidotes. 
The Westley lab reported that the reaction between 
CN and mercaptopyruvate (another type of sulfur 
donor), was catalyzed by 3-Mercaptopyruvate sul-
furtransferase (E.C. 2.8.1.2) in the cytosol and mito-
chondria[61]. When mercaptopyruvate reacts with CN, 
both SCN and cyanohydrin are formed. Mercaptopy-
ruvate enhances the antidotal effect of thiosulfate, or 
the thiosulfate + nitrite combination[19]. Westley et 
al[57] reported that serum albumin may also act as an 
endogenous sulfane sulfur donor, and can react with CN 
to form SCN. 
Sodium thiosulfate and nitrite are the active com-
ponents of the present CN antidotal combination 
therapy in the United States (Nithiodote™).
Cobalt compounds: Because cobalt has high affinity 
to CN, cobalt containing compounds can be used as 
CN antidotes. Hydroxocobalamin can react with CN 
by forming cyanocobalamin, which is excreted in the 
urine[62]. In a dog model, dicobalt edetate is superior to 
the classic nitrite + thiosulfate combination[63]. When 
cobalt chloride was administered in combination with 
thiosulfate or nitrite, it was reported that there was a 
striking enhancement between cobalt and thiosulfate, 
but not between the cobalt and the nitrite[64]. Due to its 
toxicity, cobalt chloride is not used as an antidote for 
humans[65]. 
Carbonyl compounds: CN is a nucleophile that 
reacts with carbonyl containing molecules, such as 
aldehydes and ketones, to form cyanohydrines. Sodium 
pyruvate was reported first to antagonize CN in a mice 
model[66]. The advantage of sodium pyruvate over 
the classic thiosulfate + nitrite antidotal combination 
is that it is actively transported intracellularly and 
can distribute to sites of CN localizations[67]. Sodium 
pyruvate has been reported to significantly enhance 
the protective effects of nitrite, but with thiosulfate this 
enhancement is negligible. However, by adding pyruvate 
to the combination of nitrite and thiosulfate, a striking 
protection was found[19]. The strong CN antidotal effects 
of alpha-ketoglutaric acid were reported as a result of 
cyanohydrine formation with CN[68]. 
Clorpromazine: Chlorpromazine was reported as a 
CN antidote as early as 1958[69]. The mechanism of 
its action is not known. It does not form MetHgb, bind 
CN, nor serve as sulfur donor, but it does enhance the 
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Table 1  Present cyanide therapies worldwide
  Antidotal therapy Country availability
  Sodium nitrite, amyl nitrite and sodium thiosulfate Europe, Asia (Lilly kit; Talor kit; Pasadena kit)
United States (Nithiodote™)
  Hydroxocobalamin European Union/United States (Cyanokit®)
  4-Dimethylaminophenol Germany/Austria/Netherlands
  Dicobalt edetate Netherlands/France/United Kingdom/Australia/Israel (Kelocyanor)
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environment is needed for the externally administered 
enzymes. The two major challenges of this approach 
of placing sulfur donor and Rh in a close proximity are: 
finding an appropriate sulfur donor with high sulfur 
donor reactivity, and developing an appropriate scheme 
for protecting Rh against macrophage recognition in 
the circulation[80]. Early investigations following this 
approach focused on Rh encapsulation within Carrier 
Erythrocytes[79-81]. To enhance the antidotal efficacy of 
the CN antidotal system of sulfur donor + externally 
administered Rh, organic thiosulfonates with superior 
sulfur donor reactivity were employed. When butane 
thiosulfonate was encapsulated with Rh in Carrier 
Erythrocytes, and administered in combination of 
sodium nitrite, a 14 x LD50 prophylactic protection 
was found[81]. To overcome the disadvantage of carrier 
erythrocytes (labor demanding encapsulation, prior 
blood typing), biodegradable, synthetic polymeric nano-
delivery systems were employed[82]. 
The importance of this approach became supp-
ressed when sulfur donors with higher lipophilicity, and 
higher cell penetration capability were employed. In 
1999 Baskin et al[83] reported results on the in vitro 
and in vivo efficacy studies with various synthetic 
sulfur donors with different chemical structures and 
greater lipophilicity than thiosulfate. In 2006 Ashani 
et al[84] reported that garlic, and its main component, 
allicin, were beneficial in acute CN intoxications. Allicin 
breaks down spontaneously to form a variety of 
organosulfur molecules, such as diallyl-sulfide, diallyl-
disulfide and diallyl trisulfide. In the presence of oil, 
allicin is transformed to ajoene and vinyl-dithiins[85,86]. 
Investigations of these specific garlic components 
proved that they are not superior to thiosulfate in vitro 
nor in vivo, even when they were applied with nano-
intercalated Rh[82]. More recent investigations have 
examined naturally occurring sulfur donors from garlic 
and onion that have lower Rh dependence. These sulfur 
donors demonstrate superior sulfur donor reactivity 
to thiosulfate. As a result of these investigations, 
an advanced formulation and superior therapeutic 
antidotal protection from intramuscularly administered 
methylpropyl trisulfide was reported in a mice model[87]. 
Very recent investigations are focused on other garlic 
compounds as sulfur donors that can improve the 
ancient, but still clinically used thiosulfate + nitrite 
combination (Nithiodote™). Publications of the results 
of these investigations are presently in progress. 
Mystery of nitrite/nitric oxide: Turning point 
in mechanism of CN antagonism: The traditional 
nitrite theory of MetHgb formation provided a simple 
explanation of the role of nitrites (sodium nitrites and 
amyl nitrites) in CN antagonism: Nitrites produce 
MetHgb; since MetHgb has higher affinity to CN than 
Cyt c oxidase, MetHgb removes CN from the binuclear 
heme center (Fea3-CuB) of Cyt c Oxidase, and the 
mitochondrial electron transport chain is able to return 
to its job of transferring electrons to oxygen and 
generating ATP. In this picture nitrites act as indirect 
CN scavengers[19,88]. When the nitrite + thiosulfate 
combination is applied, the CN that nitrite displaces 
reacts with thiosulfate to form SCN that is excreted in 
the urine[89,90]. However, additional research revealed 
that the blood MetHgb content needed to be around 
15% to effectively antagonize CN[91]. However, when 
the recommended amyl nitrite dose is applied, only 
about 5%-7% of Hgb is oxidized to MetHgb, and at 
these low doses amyl nitrite still acts as an efficacious 
CN antidote.
The fact that rapid onset of antidotal efficacy by 
nitrites could not be explained by MetHgb formation 
suggested one or more additional therapeutic mecha-
nisms. A turning point in understanding this mystery 
came when the mitochondrial NO synthase was 
discovered and the function of NO as a regulator in the 
electron transport chain was characterized[92].   
NO regulates the conversion of oxygen to water 
by Cyt c Oxidase as follows: Ferri-heme a3 takes up 
electrons and is reduced to ferro-heme a3, NO enters its 
active site pocket before oxygen does, a nitrosyl-ferro-
heme a3 derivative is formed that reacts with dioxygen. 
NO then dissociates from ferro-heme a3 (rate limiting 
step), and in the presence of an additional electron 
donor, nitrite is formed via an intermediate peroxynitrite. 
The cycle’s last step is the conversion of peroxynitrite 
to nitrite and water. In this way, the cycle results in the 
reduction of oxygen by NO to form water and nitrite. 
When CN enters the mitochondria, it binds to Cyt c 
Oxidase. NO can alter the CN binding to Cyt c Oxydase 
and displace CN from the Cyt c Oxidase’s binding site 
thus restoring its availability for Oxygen binding[93,94]. 
Pearce et al[95] 2003, suggested the reversal of CN 
inhibition of Cyt c Oxidase by NO occurs in the presence 
of excess reduced (ferro cyt c Oxidase) and oxygen. 
They followed the CN substitution by NO in the ferri-
heme a3, through a 5-coordinate structure by electron 
paramagnetic resonance spectroscopy. They stated 
that NO does not simply act as a reversibly bound 
competitive inhibitor, but it is also an auxiliary substrate 
that is consumed and converted to readily releasable 
nitrite. The displaced CN may then be converted to 
SCN, or be scavenged by the circulating MetHgb. When 
external nitrite is added, it boosts the availability of the 
auxiliary substrate for the Cyt c Oxidase. Along with the 
NO and MetHgb mechanisms, the vasodilation effects 
of nitrites also contribute to the their antidotal effects 
against CN. These results by the Pearce et al[95] have 
provided strong evidence toward solving the puzzle of 
the mechanisms by which  nitrite/NO antagonize CN. 
The regulatory effect of NO on Cyt c Oxidase 
became a well-studied area[96,97]. The signaling molecule 
NO is generated endogenously from L-Arginine by nitric 
oxide synthase (NOS)[98]. In CN intoxication, due to the 
histotoxic hypoxia and lactic acidosis, the NOS activity 
is decreased, and an exogenous NO source is necessary 
to protect the cellular respiration. Exogenous nitrites 
can be transformed to NO even in the condition of 
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hypoxia[99,100]. 
Studies on isolated cells (where no Hgb/MetHgb) 
confirmed that NO inhibits CN by displacing it from Cyt 
c Oxidase[94]. When the NO donor S-nitroso-N-acetyl-
DL-penicillamine was applied to the CN inhibited Cyt c 
Oxydase, CN was replaced by NO. However, when a 
NO scavenger 2-phenyl-4,4,5,5-teramethylimidazoline-
1-oxy-3 oxide (PTIO) was present, the CN antagonism 
was blocked, providing strong experimental support for 
the role of NO as a CN displacement agent[96]. In 2010, 
Leavesley et al[101] used a selective NO scavenger, PTIO 
to explore CN inhibition by nitrites. In the presence of 
CN, both the PTIO consumption and the Cyt c Oxidase 
were inhibited. However, nitrite pretreatment reversed 
the CN inhibition of NO production and Cyt c Oxidase 
activity. Conversely, pretreatment with the NO scavenger 
PTIO negated the ability of the nitrites to antagonize 
CN. Cumulatively, these studies conclude that a key 
mechanism of CN antagonism by nitrites involves the 
generation of NO that competitively displaces CN from 
Cyt c Oxydase. The NO mechanism runs parallel to the 
MetHgb mechanism. The formation of each of these 
species, NO and MetHgb, plays an independent role in 
the in vivo antagonism of CN by nitrites.
Modern theory for old molecules (Nitrites): In 
2013 Cambal et al[102] compared CN antidotal effects, 
and blood NO concentration when equimolar amounts 
of sodium nitrite and amyl nitrite were given to mice 
intraperitoneally or by inhalation after sub lethal CN 
doses. They reported that the toxic effects of iso-amyl 
alcohol formation from amyl nitrite, and the more 
efficient antidotal effects by sodium nitrite favored the 
use of sodium nitrite over iso-amyl nitrite. Agreeing with 
prior studies the authors noted that MetHgb formation 
was insufficiently rapid to explain the full antidotal 
effects of amyl nitrite[103]. They also noted that the 
sodium nitrite maintained efficacy even when MetHgb 
formation was suppressed. These studies suggested 
that the NO mechanism was primary and MetHgb 
formation secondary to the antidotal action of these 
nitrites. The authors also discussed the complexity of 
experimental interpretation when interferences due to 
anesthesia are present. 
When the CN antidotal effects of the clinically used 
anti-angina drug isosorbide dinitrate (ISDN) were 
reported, NO formation was declared as the major 
mechanism of its CN antidotal efficacy. It was reported 
that ISDN has potential advantages over sodium nitrite 
because it is relatively non-toxic, and is less likely to 
form MetHgb[104].
Present therapies and recent research investigations in 
the United States 
For treating CN poisoning, multiple antidotes exist and 
vary in regional availability: MetHgb generators (e.g., 
sodium nitrite, amyl nitrite, and dimethyl aminophenol), 
sulfur donors (e.g., sodium thiosulfate and glutathione), 
and direct binding agents (e.g., hydroxocobalamin 
and dicobalt edetate). All currently marketed antidotes 
appear to be effective. In the United States, sodium 
nitrite and sodium thiosulfate and hydroxocobalamin are 
used as cyanide antidotes, while in France and several 
other European countries, only hydroxocobalamin is 
favored[105]. Antidotal mechanisms include chelation, 
formation of stable, less toxic complexes, MetHgb 
induction, and sulfane sulfur reaction with endogenous 
Rh enzyme. Research with the goal of finding new, safer 
and more effective cyanide antidotes continues[106].
The two currently FDA approved CN countermea-
sures, Nithiodote™ (sodium nitrite and sodium thio-
sulfate) and Cyanokit® (hydroxocobalamin), each 
have limitations [e.g., sodium nitrite: intravenous (IV) 
administration, hypotension, methemoglobinemia; 
thiosulfate: IV administration, slow onset of action; 
hydroxocobalamin: IV administration, large volume]. 
Furthermore, the common requirement for IV adminis-
tration renders broad use of these CN countermeasures 
unrealistic in a mass CN exposure event. The distinct 
need remains to develop a CN countermeasure suitable 
for mass casualties. Recent investigation efforts focus 
on developing efficient, easy to administer (e.g., 
intramuscular) CN countermeasures, which may also 
be used in combination with other new generation 
countermeasures. Table 2 shows the classification of 
recent CN antidotes under development in the United 
States related to the two present CN therapies of 
Cyanokit® and Nithiodote™.     
Hydroxocobalamin 
Hydroxocobalamin is a vitamin B derivative known as 
vitamin B12a. The compound is a hygroscopic, odorless, 
dark red crystalline powder which is freely soluble in 
water and ethanol, and practically insoluble in acetone 
and diethyl ether.  It is the hydroxylated active form 
of vitamin B12 differing in that hydroxocobalamin has 
a hydroxo moiety linked to a cobalt ion while cyanoco-
balamin, known as vitamin B12 has a cyano moiety. 
The latter is used to treat pernicious anemia while 
hydroxocobalamin, based on its strong cyanide binding 
ability is a potent antidote against cyanide. Hydroxoco-
balamin has a large molecular weight and a trivalent 
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Table 2  Novel cyanide therapies in development for rapid 
IM delivery in mass casualty situations
  Novel therapy Mechanism of action Older analog
  Cobinamide Direct CN Scavenger Hydroxocobalamin
  Sulfanegen CN Transformer
(Leverages the 
mercaptopyruvate sulfur 
transferase enzyme)
Mercaptopyruvate
  Next generation 
  sulfane sulfur   
  donors
CN Transformer
(Leverages the rhodanese 
enzyme)
Thiosulfate
CN: Cyanide.
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cobalt ion that is coordinated by a tetrapyrrol ring. 
Its mode of action is attributed to its ability to form 
cyanocobalamin through binding cyanide ion by substi-
tuting the aforementioned hydroxo ligand[107,108]. 
Its pharmacokinetic properties can be characterized 
by significant plasma protein binding and the formation 
of various cobalamin-(III) complexes after intravenous 
administration. Free and total cobalamin-(III) complexes 
have half-lives of 26-31 h and overall urinary excretion 
accounts for 60%-70% of the administered dose[108]. 
The first reports of its antidotal efficacy were docu­
mented in 1952 when an experimental cyanide poisoning 
of mice was conducted. Ever since, hydroxocobalamin 
has proved its efficacy in combating cyanide intoxication 
both in animal models and humans. Mice, rats, guinea 
pigs, beagle dogs and Yorkshire pigs are some of 
the species that were included in hydroxocobalamin 
studies. Alongside the large variety of species included 
in the investigations various administration methods, 
such as intravenous, intraperitoneal and intracerebral 
micro dialysis were also tested. The studies also 
included pre- and post-poisoning set-ups and cyanide 
intoxications of various natures including inhalation and 
parenteral[109-114]. 
The efficacy of hydroxocobalamin was also seen in 
human poisonings. In these cases the antidotal effect 
of the compound, although originally developed as a 
monotherapy was seen either alone or in combination 
with other agents, such as 100% oxygen, sodium 
nitrite and sodium thiosulfate. The therapy was applied 
in cyanide poisonings originating from various sources 
including ingestion (e.g., cyanide salts and hydrogen 
cyanide) and inhalation (e.g., smoke). Survival rate 
depended on many factors but most notably hydro-
xocobalamin therapy was especially helpful when 
administered before anoxic brain damage occurred due 
to the cardiac arrest of the patients[114-116].  
Hydroxocobalamin is available as an United States 
Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) approved formulation. The 
development of the medication was initiated in the 1980s 
based on request from the Fire Brigade of Paris and 
antipoisoning center of Paris. The product was approved 
in France in 1996 and approved in the United States fast 
track in 2006, followed by EMA approval in 2007. The 
antidotal kit comprises two glass vials. Each vial contains 
2.5 g of hydroxocobalamin in the form of lyophilized 
powder, a transfer spike for reconstitution, and an 
intravenous tubing system. Prior to administration 
the product is reconstituted with 100 mL of preferably 
0.9% sodium chloride solution for injection, or lactated 
Ringer or 5% glucose solution for injection. The mixture 
is shaken and then administered intravenously over 
a period of 7.5 min. Hydroxocobalamin has shown 
itself to be an effective CN antidote via intravenous 
administration. In the pivotal studies which due to 
ethical reasons were not controlled studies but included 
patients with suspected or known cyanide-poisoning a 
survival rate of 58% was seen[108,117]. 
Cobinamide 
Cobinamide is the penultimate precursor in the biosyn-
thesis of cobalamin, lacking the dimethylbenzimidazole 
nucleotide tail coordinated to the cobalt atom in the 
lower axial position. 
Thus, whereas cobalamin has only an upper ligand 
binding site, cobinamide has two - both an upper and 
a lower - ligand binding sites. Moreover, the dimethyl-
benzimidazole group has a negative trans effect on the 
upper binding site, thereby reducing cobalamin’s affinity 
for ligands. As a result of these cobinamide has a higher 
affinity with an overall Ka of 1022 mol/L for cyanide ion 
(binding affinity for first cyanide ion is 1014 mol/L and 
for second ion is 108 mol/L) than cobalamin; for the 
sake of comparison Ka is 1012 mol/L for cobalamin. On 
the basis of Ka values cobinamide should be a more 
effective cyanide detoxifying agent than cobalamin[118]. 
Furthermore, from the aspect of antidote formulation 
an advantageous feature of cobinamide is that it is at 
least five times more water soluble (as aquohydroxo-
cobinamide) than hydroxocobalamin[119].
As in vitro affinities are not always in line with the 
in vivo conditions (e.g., intracellular proteins may bind 
cobinamide and cobalamin to varying degrees), many 
in vivo investigations on cell lines and animal models 
were carried out to examine the cyanide detoxifying 
properties of cobinamide and to compare it with cobala-
min and other antidotes.
The ability of equimolar doses of cobinamide and 
hydroxocobalamin to reverse the effects of cyanide 
exposure in New Zealand white rabbits (n = 16) was 
investigated by Brenner et al[119]. CN toxicity was 
induced by intravenous infusion and the animals were 
monitored continuously noninvasively by diffuse optical 
spectroscopy. 
Rabbits were divided into three groups: controls (n 
= 5) received intravenous saline, 6 rabbits were treated 
with intravenous hydroxocobalamin, and 5 rabbits with 
intravenous cobinamide following CN exposure. At the 
end of the sodium cyanide (NaCN) infusion (10 mg in 
60 cc normal saline for 60 min), 5 cc of normal saline or 
0.0816 millimoles of cobinamide or hydroxocobalamin 
dissolved in 5 cc of normal saline were infused over 
30 s. Cobinamide caused significantly faster and more 
complete recovery of oxy- and deoxyhemoglobin concen-
trations in CN-exposed animals over hydroxocobalamin 
with a recovery time constant of 13.8 ± 7.1 min. 
Broderick et al[118] found cobinamide to be several-
fold more effective than cobalamin in reversing CN 
inhibition of oxidative phosphorylation in mammalian 
cells; in rescuing mammalian cells and Drosophila mela-
nogaster from cyanide toxicity; and in reducing CN 
inhibition of Drosophila Malpighian tubule secretion. 
Cobinamide was as effective when administered up to 5 
min post-CN exposure as when used pre-exposure for 
prophylaxis[118].
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Currently marketed antidotal formulations for CN 
poisoning must be given by IV administration, limiting 
their use in treating mass casualties. It is advantageous 
that cobinamide could be delivered by other routes, e.g., 
oral ingestion, inhalation, too[118,120]. 
Cobinamide was studied in both an inhaled and 
intraperitoneal model of CN poisoning in mice by Chan 
et al[120]. They found cobinamide more effective than 
hydroxocobalamin, sodium thiosulfate, sodium nitrite, 
and the combination of sodium thiosulfate-sodium 
nitrite. Compared to hydroxocobalamin, cobinamide 
was 3 and 11 times more potent in the intraperitoneal 
and inhalation models, respectively. 
The use of intramuscular cobinamide sulfite to 
reverse CN toxicity-induced physiologic changes in a 
sub lethal CN exposure animal model was investigated 
by Brenner et al[121]. New Zealand white rabbits (n = 
11) were given 10 mg sodium cyanide intravenously 
over 60 min. To follow the effect of antidote, tissue oxy- 
and deoxyhemoglobin concentrations were monitored 
using quantitative diffuse optical spectroscopy and 
continuous-wave near-infrared spectroscopy. After 
completion of the CN infusion, the rabbits were treated 
intramuscularly with cobinamide sulfite (n = 6) or 
vehicle (controls, n = 5).  Intramuscular administration 
led to rapid absorption of cobinamide and the molecule 
was extremely effective at reversing the physiologic 
effects of CN. Recovery time to 63% of their baseline 
values in the central nervous system occurred within 
a mean of 1032 min in the control group and 9 min in 
the cobinamide group, with a difference of 1023 min. In 
muscle tissue, recovery times were 76 and 24 min, with 
a difference of 52 min[121]. 
When hydroxocobalamin and cobinamide were 
compared on a nonventillated swine model it was 
reported that both hydroxocobalamin and cobinamide 
rescued severely CN-poisoned swine from apnea, 
however, the dose of cobinamide was one fifth that of 
hydroxocobalamin to get the same protection[122]. 
In another study in which cobinamide sulfite was 
administered via intramuscular injection, cobinamide 
was rapidly absorbed. Mice recovered from a lethal dose 
of CN even when cobinimide was injected after they had 
been apneic for over 2 min. Cobinamide sulfite at doses 
up to 2000 mg/kg exhibited no clinical toxicity[120].
Broderick et al[123] observed that cobinamide is 
highly effective in neutralizing CN ions released by 
nitroprusside in cultured mammalian cells, Drosophila 
melanogaster, and mice. Sodium nitroprusside is 
used to treat hypertensive emergencies and acute 
heart failure. It acts by releasing NO, a highly potent 
vasodilator, but for each NO molecule released, five 
cyanide ions are released, too; thus limiting the safe use 
of this therapy. To avoid this side effect a CN scavenger 
could be beneficial when administering nitroprusside. 
It was reported that cobinamide could neutralize nitro-
prusside-released CN without having any effect on 
nitroprusside-released NO, thus it could be a valuable 
adjunct to nitroprusside therapy[123].
It is worth mentioning that in addition to cyanide, 
cobinamide is capable of reacting with NO. However, the 
binding constant of cobinamide is substantially lower 
for NO than it is for cyanide (≈ 1022 mol/L for cyanide; 
≈ 1010 mol/L for NO)[124]. On this basis when given in 
excess of available CN, cobinamide may potentially 
induce vasoconstriction and increase blood pressure, as 
has also been observed with hydroxocobalamin[125]. 
It can be concluded that cobinamide and its sulfite­
salt are effective cyanide detoxifying agents that 
have the potential to serve as CN antidotes for smoke 
inhalation victims and persons exposed to CN used as a 
weapon of mass destruction.
Sulfanegen 
Sulfanegen is the water-soluble prodrug of 3-mer-
captopyruvate that was developed in the early 1990’s 
to overcome the problem of the relatively low serum 
stability of the sulfur donor 3-mercaptopyruvate[126]. 
Sulfanegen is a dimer that dissociates non-enzy-
matically in physiological systems to two equivalents 
of the monomer 3-mercaptopyruvate. The endogenous 
enzyme 3-mercaptopyruvate sulfur transferase (3-MPST) 
catalyzes the transfer of reactive sulfane sulfur from 
3-mercaptopyruvate to CN resulting in the formation of 
thiocyanate and pyruvate[127,128]. Compared to Rh, the 
3-MPST enzyme is available in both the mitochondria 
and cytoplasm, whereas rhodanese is present only in 
the mitochondria of hepatic and renal tissues. It was 
shown that a high amount of 3-MPST exists in the tissue 
of the brain, specifically in the cerebellum. This strong 
presence of detoxifying enzyme in the brain holds 
therapeutic promise, because much of the damage from 
CN intoxication is localized in the heart and brain. 
The other potential advantage with sulfanegen is 
the fact that it exerts its effects in less than 3 min. With 
hydroxocobalamin, a fifteen­minute intravenous infusion 
is required to deliver a standard dose. The discovery of 
the highly water-soluble sulfanegen triethanolamine for 
development as an intramuscular injectable antidote was 
reported by Patterson et al[129]. The potential of intramu-
scular and intravenous sulfanegen sodium treatment to 
reverse CN effects was evaluated in a rabbit model (n = 
35). Changes associated with CN exposure and reversal 
were monitored by diffuse optical spectroscopy and 
continuous wave near infrared spectroscopy. Sulfanegen 
sodium was shown to reverse the effects of CN exposure 
on oxy­ and deoxyHgb rapidly, significantly faster than 
in case of control animals. Red blood cell CN levels also 
returned to normal levels faster with both intramuscular 
and intravenous sulfanegen sodium treatment than with 
control treatments[126]. 
Severe CN toxicity - occurrence of severe lactic 
acidosis accompanied by significant elevation in blood 
CN levels - was induced in juvenile pig models to 
demonstrate the CN antagonism capability of sulfane-
gen[127]. Anesthetized pigs (n = 8) received a high-
dose intravenous infusion of sodium nitroprusside SNP 
(100 mg/h) for 2 h to induce CN toxicity. Then, four 
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pigs received 3 doses of sulfanegen sodium (2.5 g i.v.) 
and four pigs received placebos. Administration of the 
sulfanegen antidote resulted in progressively significant 
reduction in blood lactate and CN levels with 100% 
survival (P < 0.05), whereas the placebo-treated pigs 
deteriorated and did not survive (P < 0.05). In another 
group of pigs (n = 6) severe CN toxicity was induced 
by NaCN and at peak toxicity (value determined during 
preliminary measurements), the animals were given 
sodium sulfanegen (2.5 g i.v.) followed by a repeat dose 
60 min later in surviving animals. Without sulfanegen 
the NaCN injection used in this study resulted in CN 
toxicity, accompanied by severe lactic acidosis, and 
mortality in all the pigs. Sodium sulfanegen reversed 
NaCN-toxicity and prevented mortality in all the pigs 
treated with this antidote[127].
The combination of cobinamide and sulfanegen 
was explored by Chan et al[120] using a non-lethal and 
two different lethal models - a CN injection and a CN 
inhalation - of CN poisoning in mice. The effect of the 
two antidotes was found to be at least additive when 
used together in all the models used in this study. At 
doses where all animals died with either drug alone, 
the combination yielded 80% and 40% survival in the 
injection and inhalation models, respectively. Similarly, 
drug doses that yielded only 40% survival with either 
drug alone, yielded 80% and 100% survival with the 
combination therapy in the injection and inhalation 
models, respectively[120].
New sulfur donors 
As indicated earlier, very recent investigations in the 
Petrikovics lab have focused on naturally occurring sulfur 
donors with lower Rh dependence (scavenger type 
mechanism), that have superior sulfur donor reactivity 
to thiosulfate. These sulfur donors were first extracted 
from garlic compounds and show great promise as su-
ccessors to the ancient antidote thiosulfate, which is 
still clinically used in the thiosulfate + nitrite combina-
tion (Nithiodote™). Publications of the results of these 
investigations are presently in progress. 
CONCLUSION
Table 1 shows the recent therapies in the US and some 
European countries, and Table 2 indicates the relations 
of the new generation CN antidotes to the recent CN 
therapies in the US. The roots of the present clinically 
employed therapies reach back to research efforts 
initiated in the early 20th century. CN intoxication from 
suicides, homicides, fires, industrial accidents, and 
potential terrorist attacks, presents a tremendous need 
for new, rapidly acting and efficient tools to antagonize/
treat the toxic and lethal effects of CN in both isolated 
and mass casualty scenarios. 
The lead new generation CN countermeasure cobina-
mide is a successor of the ancient, but still employed 
therapy of hydroxocobalamin. Sulfanegen is a next 
generation successor of mercaptopyruvate. The new 
generation of sulfane sulfur donors are successors of 
the classic sulfur donor sodium thiosulfate. These novel 
sulfane sulfur donors are organo-sulfur molecules that 
were originally found in garlic and onion. They have 
other potentially positive health effects[130] and work 
efficiently against CN intoxication without requiring the 
catalytic mediation of sulfurtransferases. 
New combinations, formulations and nano-delivery 
systems of these next generation antidotes with enhan-
ced bioavailability, and efficacy, provide strong hope 
for the gradual replacement of present therapies with 
improved new drugs and therapies for CN intervention.
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